Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:35:10 EDT Thu 25 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:MRK from 2023-04-26 to 2024-04-25 - 128 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-25 06:30U:MRKNews ReleaseMerck Announces First-Quarter 2024 Financial Results
2024-04-19 07:04U:MRKNews ReleaseHealth Canada Approves KEYTRUDA(TM) as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-co
2024-04-04 06:45U:MRKNews ReleaseMerck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA(TM) (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
2024-04-03 08:00U:MRKNews ReleaseREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
2024-04-01 06:45U:MRKNews ReleaseMerck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
2024-03-28 09:18U:MRKNews ReleaseHow We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
2024-03-28 06:45U:MRKNews ReleaseEuropean Commission Approves Merck's KEYTRUDA(TM) (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
2024-03-26 18:21U:MRKNews ReleaseFDA Approves Merck's WINREVAIR(TM) (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
2024-03-26 09:32U:MRKNews ReleaseMerck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
2024-03-21 06:45U:MRKNews ReleaseMerck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA(TM) (pembrolizumab) Plus Maintenance LYNPARZA(TM) (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
2024-03-19 09:00U:MRKNews ReleaseMerck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
2024-03-15 16:23U:MRKNews ReleaseFarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
2024-03-15 06:45U:MRKNews ReleaseMerck's KEYTRUDA(TM) (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2024-03-13 03:00U:MRKNews ReleaseMerck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL(TM)9
2024-03-11 08:15U:MRKNews ReleaseMerck Completes Acquisition of Harpoon Therapeutics, Inc.
2024-03-06 10:25U:MRKNews ReleaseGilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
2024-03-05 08:30U:MRKNews ReleaseIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
2024-03-05 06:45U:MRKNews ReleaseMerck to Participate in the Barclays 26th Annual Global Healthcare Conference
2024-03-04 06:45U:MRKNews ReleaseMerck to Participate in the Leerink Partners Global Biopharma Conference 2024
2024-02-27 06:45U:MRKNews ReleaseMerck to Participate in the TD Cowen 44th Annual Health Care Conference
2024-02-23 06:20U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA(TM) (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
2024-02-20 06:45U:MRKNews ReleaseFDA Grants Priority Review to Merck's Application for KEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
2024-02-15 08:45U:MRKNews ReleaseGlobal Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
2024-02-13 11:52U:MRKNews ReleaseMerck Is Inspiring Innovation Through Diversity and Inclusion
2024-02-12 07:05U:MRKNews ReleaseHealth Canada Approves KEYTRUDA ® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours exp
2024-02-12 07:05U:MRKNews ReleaseHealth Canada Approves KEYTRUDA ® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours exp
2024-02-08 07:00U:MRKNews ReleaseMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
2024-02-08 07:00U:MRKNews ReleaseMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
2024-02-05 06:33U:MRKNews ReleaseMerck Animal Health to Acquire Elanco ¢ € ™s Aqua Business
2024-02-05 06:33U:MRKNews ReleaseElanco Announces Sale of Aqua Business for $1.3 Billion
2024-02-01 06:30U:MRKNews ReleaseMerck Announces Fourth-Quarter and Full-Year 2023 Financial Results
2024-01-29 08:46U:MRKNews ReleaseThe Wall Street Journal Names Merck Among Top 10 Best-Managed Companies
2024-01-27 10:00U:MRKNews ReleaseMerck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
2024-01-26 12:16U:MRKNews ReleaseUnexpected Inspiration for More Sustainable Drug Development at Merck
2024-01-26 10:00U:MRKNews ReleaseMerck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
2024-01-23 14:44U:MRKNews ReleaseMerck Announces Second-Quarter 2024 Dividend
2024-01-19 06:45U:MRKNews ReleaseMerck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
2024-01-15 08:15U:MRKNews ReleaseMerck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
2024-01-12 17:30U:MRKNews ReleaseFDA Approves Merck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
2024-01-08 07:30U:MRKNews ReleaseMerck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
2024-01-05 06:45U:MRKNews ReleaseMerck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
2024-01-03 06:45U:MRKNews ReleaseMerck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-22 08:00U:MRKNews ReleasePatritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2023-12-21 07:05U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
2023-12-21 07:05U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
2023-12-20 16:30U:MRKNews ReleaseMerck Provides U.S. Regulatory Update on Gefapixant
2023-12-20 06:45U:MRKNews ReleaseMerck to Participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference
2023-12-19 06:45U:MRKNews ReleaseFDA Grants Priority Review to Merck ¢ € ™s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
2023-12-18 06:45U:MRKNews ReleaseEuropean Commission Approves Merck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy for New First-Line Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ¢ ‰ ¥1) and Advanced Biliary Tract Cancer
2023-12-15 17:00U:MRKNews ReleaseFDA Approves Expanded Indication for KEYTRUDA ‚ ® (pembrolizumab) Plus Padcev ‚ ® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer
2023-12-14 19:00U:MRKNews ReleaseFDA Approves Merck ¢ € ™s WELIREG ‚ ® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
2023-12-14 06:32U:MRKNews ReleaseModerna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
2023-12-11 06:45U:MRKNews ReleaseMerck Animal Health Receives Positive CVMP Opinion for an Injectable Formulation of BRAVECTO ‚ ® (Fluralaner) for Use in Dogs
2023-12-11 06:45U:MRKNews ReleaseMerck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA ‚ ® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
2023-12-08 06:45U:MRKNews ReleaseMerck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA ‚ ® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
2023-12-07 06:45U:MRKNews ReleaseMerck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA ‚ ® (pembrolizumab) Plus LYNPARZA ‚ ® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
2023-11-30 17:00U:MRKNews ReleaseFDA Grants Priority Review to Merck ¢ € ™s Application for KEYTRUDA ‚ ® (pembrolizumab) Plus Padcev ‚ ® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer
2023-11-29 09:00U:MRKNews ReleaseAWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
2023-11-28 13:17U:MRKNews ReleaseMerck Announces First-Quarter 2024 Dividend
2023-11-28 06:45U:MRKNews ReleaseMerck ¢ € ™s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
2023-11-21 06:45U:MRKNews ReleaseMerck to Acquire Caraway Therapeutics, Inc.
2023-11-20 06:45U:MRKNews ReleaseMerck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-10 07:40U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA ‚ ® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
2023-11-08 06:45U:MRKNews ReleaseMerck to Participate in the Jefferies London Healthcare Conference
2023-11-01 06:50U:MRKNews ReleaseMerck to Participate in the UBS BioPharma Conference
2023-11-01 06:45U:MRKNews ReleaseFDA Approves Merck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
2023-10-26 06:30U:MRKNews ReleaseMerck Announces Third-Quarter 2023 Financial Results
2023-10-25 07:30U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
2023-10-25 07:30U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
2023-10-24 08:04U:MRKNews ReleaseMerck Senior Vice President Sarah Aiosa Named to Most Powerful Latinas List
2023-10-22 10:30U:MRKNews ReleaseKEYTRUDA ‚ ® (pembrolizumab) Plus Padcev ‚ ® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
2023-10-21 08:45U:MRKNews ReleaseMerck ¢ € ™s WELIREG ‚ ® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
2023-10-20 10:00U:MRKNews ReleaseMerck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
2023-10-20 08:02U:MRKNews ReleaseMerck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer
2023-10-20 08:01U:MRKNews ReleaseKEYTRUDA ‚ ® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-10-20 08:00U:MRKNews ReleaseKEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
2023-10-19 19:30U:MRKNews ReleaseDaiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
2023-10-17 06:45U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for PREVYMIS ‚ ® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
2023-10-16 19:00U:MRKNews ReleaseFDA Approves KEYTRUDA ‚ ® (pembrolizumab) for Treatment of Patients With Resectable (T ¢ ‰ ¥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery
2023-10-16 06:45U:MRKNews ReleaseEuropean Commission Approves KEYTRUDA ‚ ® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
2023-10-13 07:45U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ¢ ‰ ¥1)
2023-10-10 06:45U:MRKNews ReleaseMerck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
2023-10-05 08:17U:MRKNews ReleaseMerck is Collaborating to Address Antimicrobial Resistance
2023-10-05 07:00U:MRKNews ReleaseMerck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
2023-10-05 06:45U:MRKNews ReleaseMerck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
2023-09-28 06:45U:MRKNews ReleaseMerck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
2023-09-22 06:45U:MRKNews ReleaseMerck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA ‚ ® (pembrolizumab) Plus LENVIMA ‚ ® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
2023-09-20 06:45U:MRKNews ReleaseFDA Grants Priority Review to Merck ¢ € ™s Application for KEYTRUDA ‚ ® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2023-09-19 06:45U:MRKNews ReleaseFDA Accepts for Priority Review Merck ¢ € ™s Supplemental New Drug Application for WELIREG ‚ ® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
2023-09-15 09:10U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA ‚ ® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
2023-09-11 07:45U:MRKNews ReleaseMerck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
2023-09-07 06:45U:MRKNews ReleaseEuropean Commission Expands Merck ¢ € ™s ERVEBO ‚ ® [Ebola Zaire Vaccine, (rVSV Ž ”G-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
2023-09-05 08:00U:MRKNews ReleaseLong-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL ‚ ®9 Published in Pediatrics
2023-09-05 06:45U:MRKNews ReleaseMerck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-29 06:50U:MRKNews ReleaseEuropean Commission Approves KEYTRUDA ‚ ® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ¢ ‰ ¥1)
2023-08-29 06:45U:MRKNews ReleaseMerck to Participate in the Citi 18th Annual BioPharma Conference
2023-08-25 06:30U:MRKNews ReleaseMerck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
2023-08-25 06:15U:MRKNews ReleaseMerck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA ‚ ® (pembrolizumab) Plus LENVIMA ‚ ® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2023-08-24 06:45U:MRKNews ReleaseLYNPARZA ‚ ® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2023-08-16 08:02U:MRKNews ReleaseMerck Employee Talks Pride, Pediatrics and Parenting
2023-08-08 08:16U:MRKNews ReleaseMerck Is Harnessing Innovation To Reach Indigenous Communities
2023-08-07 08:30U:MRKNews ReleaseAnixa Biosciences Announces Opening of Enrollment for Keytruda ‚ ® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
2023-08-03 06:45U:MRKNews ReleaseU.S. FDA Approves Merck ¢ € ™s ERVEBO ‚ ® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
2023-08-01 06:30U:MRKNews ReleaseMerck Announces Second-Quarter 2023 Financial Results
2023-07-28 06:45U:MRKNews ReleaseMerck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
2023-07-27 06:45U:MRKNews ReleaseMerck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
2023-07-26 06:45U:MRKNews ReleaseMerck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA ‚ ® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
2023-07-25 12:58U:MRKNews ReleaseMerck Announces Fourth-Quarter 2023 Dividend
2023-07-25 08:11U:MRKNews ReleaseMerck is Safeguarding the Environment Through Green Chemistry
2023-07-21 07:50U:MRKNews ReleaseMerck Receives Positive EU CHMP Opinion for KEYTRUDA ‚ ® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ¢ ‰ ¥1)
2023-07-19 06:45U:MRKNews ReleaseMerck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
2023-07-17 15:55U:MRKNews Release3 Ways Merck Supports the LGBTQ+ Community
2023-06-29 06:45U:MRKNews ReleaseMerck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
2023-06-20 06:45U:MRKNews ReleaseMerck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-06-16 16:04U:MRKNews ReleaseMerck Completes Acquisition of Prometheus Biosciences, Inc.
2023-06-16 06:45U:MRKNews ReleaseKEYTRUDA ‚ ® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
2023-06-13 16:05U:MRKNews ReleaseU.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION ‚ ® (sugammadex)
2023-06-12 06:45U:MRKNews ReleaseMerck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023
2023-06-08 06:45U:MRKNews ReleaseFDA Accepts Application for Merck ¢ € ™s KEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
2023-06-06 06:50U:MRKNews ReleaseU.S. FDA Approves New Indication for Merck ¢ € ™s PREVYMIS ‚ ® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
2023-06-06 06:45U:MRKNews ReleaseMerck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-05 08:01U:MRKNews ReleaseModerna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
2023-06-03 09:00U:MRKNews ReleaseMerck ¢ € ™s KEYTRUDA ‚ ® ‚  (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
2023-06-03 08:00U:MRKNews ReleaseKEYTRUDA ‚ ® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
2023-05-25 17:00U:MRKNews ReleaseKEYTRUDA ‚ ® (pembrolizumab) Plus LENVIMA ‚ ® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
2023-05-23 14:45U:MRKNews ReleaseMerck Announces Third-Quarter 2023 Dividend
2023-05-03 06:45U:MRKNews ReleaseMerck to Participate in Bank of America Securities 2023 Healthcare Conference
2023-04-27 06:30U:MRKNews ReleaseMerck Announces First-Quarter 2023 Financial Results